SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 62,900 shares of the Company’s common stock at an exercise price per share of $2.30, which was the closing price per share of the Company’s common stock as reported by NASDAQ on October 1, 2026, and (ii) restricted stock units (RSUs) representing 72,700 shares of its common stock to two newly-hired non-executive employees, including the newly-hired employee receiving the non-qualified stock options referenced above. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously announced registered public offering (the “Offering”) on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The Offering consisted of 36,047,919 shares of common stock at a public offering price of $2.90 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,883,121 shares of common stock at a public offering price of $2.899 per pre-funded warrant, in each case, accompanied by common warrants to purchase an aggregate of 49,310,352 shares of common stock.

The clinical milestone-linked common warrants are tied to Pyxis Oncology’s public disclosure of overall survival data (the “OS Data Release Date”) from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (“MICVO”) in second-line and beyond (“2L+”) recurrent/metastatic head and neck squamous cell carcinoma (“R/M HNSCC”), which is expected to occur in the first half of 2027. The warrants have an exercise price of $3.50 per common share, a 21% premium to the $2.90 public offering price. If all milestone-linked warrants are exercised in full for cash, the Offering would provide Pyxis Oncology with approximately $172.6 million in additional gross proceeds, for a total of approximately $282.6 million in gross proceeds, before deducting applicable expenses.

The common warrants will become exercisable only upon approval by the Company’s stockholders of an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock and the effectiveness of that amendment (the date of such effectiveness, the “Charter Amendment Effective Date”), and will expire upon the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of (x) the Charter Amendment Effective Date and (y) the OS Data Release Date.

The Offering included participation from new and existing institutional investors, including OrbiMed, GordonMD Global Investments, BVF Partners, Coastlands Capital, and RTW Investments.

Leerink Partners, Guggenheim Securities and Wells Fargo Securities acted as joint bookrunning managers for the Offering.

Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ R/M HNSCC, and for working capital and general corporate purposes. The Company also plans to disclose updated data from its ongoing Phase 1/2 combination dose escalation study of MICVO and Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for first-line (1L) R/M HNSCC patients in the fourth quarter of 2026.

About Pyxis Oncology

Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release, including without limitation statements regarding the Offering, including the anticipated total gross proceeds therefrom (including from any exercise of the common warrants); the Company’s ability to obtain stockholder approval of, and to effect, the amendment to its certificate of incorporation required for the common warrants to become exercisable, and the timing thereof; the timing of the OS Data Release Date, which will affect the period during which the common warrants may be exercised; the Company’s intended use of the net proceeds from the Offering; the Company’s plans to develop, manufacture and commercialize MICVO; the timing and progress of the Company’s ongoing clinical trials and the expected results thereof; the plans and objectives of management; and the future results of operations and financial position of the Company, are forward-looking statements. These statements are neither promises nor guarantees, but are statements that involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: market and other conditions and the Company’s ability to obtain the stockholder approval required for the common warrants to become exercisable; the timing and results of the overall survival analysis from the Company’s Phase 1 monotherapy study of MICVO; the timing and results from the Company’s Phase 1/2 dose escalation study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA®; the risks inherent in drug research and development; the Company’s projected cash runway and potential needs for additional funding; the lengthy, expensive and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; the Company’s reliance on third parties and collaborators to conduct clinical trials, manufacture its product candidate, and develop and commercialize its product candidate; the Company’s ability to compete successfully against other drug candidates; and volatility in the price of the Company’s common stock. Accordingly, investors should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Additionally, investors should read the risk factors in the section titled “Risk Factors” set forth in Part II, Item 1A of the Company’s Quarterly Report on Form 10-Q filed on August 13, 2026, in the preliminary prospectus supplement relating to the Offering, and in the Company’s other filings, each of which is on file with the Securities and Exchange Commission.

Pyxis Oncology Contact:
IR@pyxisoncology.com

Vancouver, British Columbia, Oct. 02, 2026 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) announces the results of its 2026 Annual General Meeting of shareholders and the grant of deferred share units to certain directors of the Company.

Annual General Meeting

The Company held its Annual General Meeting on September 29, 2026. All proposed resolutions, as described in the notice of meeting and management information circular dated August 17, 2026, were approved by the shareholders of the Company.

Following the Meeting, the Board of Directors of the Company consists of Christian Kargl-Simard, Leif Nilsson, Dr. Shane Ebert, Richard Colterjohn, Dr. Paul West-Sells, Tony Scott, Nalaine Morin, and David Farrell. Mr. Scott, Ms. Morin, and Mr. Farrell were newly elected to the Board as part of the Company’s previously announced Board renewal process (see July 29, 2026 press release).

Grant of Share Compensation Plan Incentive Awards

The Company also announces the grant of deferred share units (“DSUs”) under its Share Compensation Plan to newly elected non-executive directors. The Company has awarded an aggregate of 180,288 DSUs, based on the 5-day volume weighted average price of the Company’s common shares on the TSX Venture Exchange of C$0.52/share.

The DSUs will vest 12 months from the date of grant and will be settled following the departure of the holder from the Company, in accordance with the terms of the Company’s Share Compensation Plan.

A copy of the Share Compensation Plan is available on the Company’s website at www.surgecopper.com/investors/agm-materials or under the Company’s profile on SEDAR+ at www.sedarplus.ca.

About Surge Copper Corp.

Surge Copper Corp. is a Canadian resource company advancing one of British Columbia’s emerging copper districts. The Company’s 100%-owned Berg Copper Project hosts a large-scale copper-molybdenum-silver-gold deposit in central British Columbia supported by a Pre-Feasibility Study and Mineral Reserve estimate that define a development pathway for a long-life copper project with significant molybdenum, silver, and gold by-product production.

In addition to the Berg deposit, Surge controls a large, contiguous mineral claim package that includes multiple advanced porphyry deposits, including the Ox and Seel deposits adjacent to the past-producing Huckleberry Mine. Collectively, the Company’s assets position Surge as a potential long-term contributor to Canada’s critical minerals strategy through the responsible development of copper, molybdenum, and associated metals.

Surge is committed to advancing its projects through early engagement and collaboration with First Nations and local communities, with a focus on transparent communication, relationship building, and respectful, constructive dialogue.

For more information, visit www.surgecopper.com

On Behalf of the Board of Directors

“Leif Nilsson”
Chief Executive Officer

For further information, please contact:
Riley Trimble, Corporate Communications & Development
Telephone: +1 604 639 3852
Email: info@surgecopper.com
X: @SurgeCopper
LinkedIn: Surge Copper Corp
https://www.surgecopper.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This News Release contains forward-looking statements, which relate to future events. In some cases, you can identify forward-looking statements by terminology such as “will”, “may”, “should”, “expects”, “plans”, or “anticipates” or the negative of these terms or other comparable terminology. All statements included herein, other than statements of historical fact, are forward-looking statements, including but not limited to statements regarding the vesting and settlement of the DSUs granted by the Company. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results, level of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Such uncertainties and risks may include, among others, actual results of the Company’s exploration activities being different than those expected by management, delays in obtaining or failure to obtain required government or other regulatory approvals, the ability to obtain adequate financing to conduct its planned exploration programs, inability to procure labour, equipment, and supplies in sufficient quantities and on a timely basis, equipment breakdown, and bad weather. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect the Company’s current judgment regarding the direction of its business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions, or other future performance suggestions herein. Except as required by applicable law, the Company does not intend to update any forward-looking statements to conform these statements to actual results.

Into The Millennium – Homecoming: Live in Canada coming to Rogers Centre, February 2027

The band’s only 2027 North American stadium shows

Rogers customers get exclusive ticket presale on October 5

Rogers Brings Backstreet Boys to Canada

TORONTO, Oct. 02, 2026 (GLOBE NEWSWIRE) — It’s going to be Larger than Life, Canada! Rogers and Live Nation Canada today announced that Rogers is bringing one of the best-selling bands of all time, the Backstreet Boys, to Canada for a four-concert residency at Rogers Centre in Toronto on February 12, 13, 19 and 20, 2027. Rogers customers get exclusive ticket presale access on October 5, with public sale beginning on October 9.

Into the Millennium – Homecoming: Live in Canada will be the band’s only North American stadium shows of 2027.  This once-in-a-lifetime experience gives fans the chance to see the legendary Millennium album brought to life, alongside a selection of the group’s greatest hits, including beloved classics such as “I Want It That Way” and “Everybody (Backstreet’s Back)”, along with songs more rarely performed live such as “It’s Gotta Be You” and “The Perfect Fan”.

Canada has long held a special place in the Backstreet Boys’ story. It was the group’s first major breakthrough in North America, and Canadian audiences embraced the band from the start. Decades later, that connection remains as strong as ever – rooted in the fans who have grown up with their music and continue to make every Canadian stop truly feel like a homecoming.

“Fans from around the world are excited to see this iconic group live, so we jumped at the opportunity to bring the Backstreet Boys to Canada,” said Terrie Tweddle, Chief Brand and Communications Officer, Rogers. “For more than three decades, the Backstreet Boys have built a passionate fan base and sold-out arenas around the world, and we’re excited to create unforgettable opportunities for fans and our customers.”

“Few artists have a connection with Canadian fans as enduring and meaningful as the Backstreet Boys,” said Erik Hoffman, President of Music, Live Nation Canada. “We’re thrilled to welcome them back to Toronto for this special Homecoming series and celebrate a bond that has spanned generations.”

“Canada was one of the first places to embrace us, and the love and support we’ve received from our fans there has meant so much from the very beginning,” said Brian Littrell. “Coming back feels incredibly special. It is a chance for all of us to celebrate the memories we’ve made together and create some new ones.”

The Toronto concert series follows the band’s unprecedented success with their Into the Millennium Sphere shows in Las Vegas, as well as their 10-show stadium residency in Düsseldorf, Germany, which launched last week. The Düsseldorf shows have delivered a major full-circle moment, as the band thrilled fans by reviving the legendary Into the Millennium Tour entrance – soaring in from the sky on hoverboards, just as they did in 1999, before opening the show with “Larger Than Life.” The shows have continued to celebrate the Backstreet Boys’ defining Millennium era, a cultural moment in time that cemented their place in pop history.

Exclusive Benefits for Rogers Customers
Rogers is the presenting sponsor of the Into the Millennium – Homecoming: Live in Canada residency. In addition to early access to tickets, Rogers customers will have access to premium experiences, including the chance to win VIP meet-and-greets, through the Rogers Beyond the Seat program. 

Rogers will also give customers and fans the chance to win thousands of tickets, including grand prizes with airfare and accommodation in Toronto to see the Backstreet Boys at Rogers Centre. Details on contesting will be announced at a later date.

Rogers also launched a TV ad today featuring the Backstreet Boys and Canadian actor Michael Cera to promote the perks of being a Rogers customer, including presale access to Backstreet Boys.

Follow Rogers on Instagram for the latest updates on how to win tickets and VIP meet-and-greet opportunities.

Official Concert & VIP Hotel Experience Packages
Please & Thank You, the direct-to-fan experience company, is the official Concert & VIP Hotel Experience Package partner for Into the Millennium – Homecoming: Live in Canada at Rogers Centre. Packages will be available beginning October 5 through the Rogers presale.

Packages include premium reserved seating at Rogers Centre, hotel accommodations, and a range of added perks: priority entry and exclusive lounge access at the Backstreet Boys YYZ Terminal – Toronto fan experience and at the show, a BSB-curated gifting kit, Please & Thank You’s on-site concierge service, and more. For more information and early access to tickets through Please & Thank You packages, visit backstreetboys.please.co.
Meet-and-greets are not included in any package.

Backstreet Boys YYZ Terminal – Toronto
The Backstreet Boys are opening the Backstreet Boys YYZ Terminal – Toronto, an immersive fan pop-up in Toronto inspired by the Millennium album’s airport cover. It’s home to the official BSB merch store, with exclusive Homecoming collectibles, Millennium-era photo moments and fan events throughout the residency. Please & Thank You VIP package holders get priority entry and exclusive lounge access. For more information, please visit backstreetboys.com.

TICKETS:

  • Exclusive Presale for Rogers Customers: Monday, October 5 at 10am – Tuesday, October 6 at 10pm ET
  • Backstreet Army Presale: Tuesday, October 6 from 10am – 10pm ET
  • Artist Sign Up Presale: Wednesday, October 7 from 10am – 10pm ET; Fans can sign up HERE now through Monday, October 5, at 10pm ET
  • Live Nation All Access Presale: Thursday, October 8 from 10am to 10pm ET
  • Rogers Centre Presale: Thursday, October 8 from 10am to 10pm ET
  • General On Sale: Friday, October 9, at 10am ET Ticketmaster.ca

About Rogers Communications Inc.
Rogers is Canada’s communications, sports and entertainment company, and its shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For more information, please visit rogers.com or https://about.rogers.com/investor-relations/.

About Backstreet Boys  
For more than 30 years the Backstreet Boys have delivered the finest pop music one has to offer, making them one of pop’s most influential performers. With countless #1s, record-setting tours, numerous awards and worldwide sales in excess of 130 million, BSB has been recognized as the best-selling boy band in history.

The Backstreet Boys are the first ever pop group to play at Sphere, with 47 sold-out shows and counting, the band has played to nearly 750,000 fans and have received critical acclaim and praise for their electrifying performances, state-of-the-art visuals, and groundbreaking stage production. They will continue their run with more dates in 2026 and 2027 further cementing the residency as one of the most successful and innovative live entertainment experiences in Las Vegas history. This fall the Backstreet Boys are performing a sold-out 10-show stadium residency at Düsseldorf’s MERKUR SPIEL-ARENA as a celebration of the country where their international success first began.

The Backstreet Boys also celebrated the 25th anniversary of their chart-topping, 5-time GRAMMY- nominated album, Millennium with Millennium 2.0 in 2025. This deluxe re-issue features 25 tracks, including all 12 remastered originals, live recordings, demos, including “I Want It That Way” and B-sides, including the alternate version of “I Want It That Way.”

Over the years, the Backstreet Boys have repeatedly captivated millions of people with their impressive catalog of hit songs and creative partnerships and continue to be larger than life. 

About Live Nation Entertainment:
Live Nation Entertainment (NYSE: LYV) is the world’s leading live entertainment company comprised of global market leaders: Ticketmaster, Live Nation Concerts, and Live Nation Media & Sponsorship. For additional information, visit www.livenationentertainment.com.

MEDIA CONTACTS:

Backstreet Boys:
The Lede Company
Cara Hutchison – cara.hutchison@ledecompany.com
Chris Iacullo – chris.Iacullo@ledecompany.com

Rogers:
media@rci.rogers.com

Live Nation Canada:
Tonisha Bath – tonishabath@livenation.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3f12b9ca-d43b-43b0-b7ee-958be9e62e67

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN AUSTRALIA, CANADA, HONG KONG, NEW ZEALAND, SOUTH AFRICA AND SOUTH KOREA, OR ANY JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

The Agreement
The Board of Directors of AKVA group ASA (“AKVA”, “AKVA group”, or the “Company”) and Pontos Bidco AS (the “Offeror”), a Norwegian private limited liability company indirectly owned by Yanmar Holdings Co., Ltd. (“Yanmar”), are pleased to announce that they have entered into a transaction agreement (the “Transaction Agreement”) for a recommended voluntary cash offer (the “Offer”) by the Offeror to acquire all issued and outstanding shares in AKVA (the “Shares”, and each a “Share”).

A cash consideration of NOK 161 (the “Offer Price”) will be offered for each Share. The Offer Price represents a premium of:

  • 57% compared to the undisturbed, dividend adjusted closing trading price of NOK 102.5 for the Shares on Euronext Oslo Børs on 7 April 2026, being the last trading day prior to announcement of AKVA’s strategic review;
  • 62% compared to the 30-trading days dividend adjusted volume weighted average share price of NOK 99.3 in the period ending 7 April 2026; and
  • 67% compared to the 60-trading days dividend adjusted volume weighted average share price of NOK 96.2 in the period ending 7 April 2026.

Board recommendation
The Offer is a result of the strategic review initiated by the Board of Directors of AKVA (the “Board”), as announced on 8 April 2026, with the aim to maximize shareholder value. Following announcement of the strategic review, the Company received high-quality interest regarding a potential sale of the Company, and the Company and its advisors have been in dialogue with several interested parties to evaluate the viability and the potential terms for a transaction.

After careful consideration of the Company’s available options, the Board’s assessment is that the Offer represents the most attractive alternative to maximize shareholder value. The Board has therefore unanimously resolved to recommend that the shareholders accept the Offer.

The Board believes that Yanmar, as a long-term industrial owner, can support AKVA in realizing its long-term potential through access to complementary technologies, global capabilities and resources.

The complete statement of the Board regarding the Offer (the “Board Recommendation”) is appended to this notice. The Board Recommendation is not made pursuant to Sections 6-16 and 6-19 of the Norwegian Securities Trading Act and a separate statement will, pursuant to a decision by the Norwegian Financial Supervisory Authority (the “NFSA”), be made by an independent third party in this respect.

Pre-Acceptances
Shareholders in AKVA representing approximately 92% of the Shares (excluding the Company’s treasury shares), have undertaken, subject to customary conditions, to tender their shares into the Offer (the “Irrevocable Undertakings”). The Irrevocable Undertakings may not be withdrawn in the event of the launch of a competing offer. Shareholders who have given Irrevocable Undertakings include:

  • Egersund Group AS
  • Israel Corporation LTD
  • all members of the Board and the executive management of AKVA
  • Pareto Asset Management AS, including discretionary portfolios managed by Pareto Asset Management AS
  • Nordea Investment Management AB
  • Alfred Berg

As part of the Irrevocable Undertakings, the committed shareholders have agreed not to directly or indirectly, solicit, encourage, invite or seek alternative proposals for any competitive offer.

Identity of the Offeror and strategic rationale
The Offeror is Pontos Bidco AS (pending name change from NFH 260570 AS), business registration no. 937 943 121, a newly established Norwegian limited liability company indirectly owned by Yanmar.

Yanmar is a diversified global industrial group with over a century of engineering heritage and a deeply rooted culture of innovation. Founded in 1912, Yanmar is a family-owned business now led by Takehito Yamaoka, President and Representative Director.

Yanmar has over time evolved from its origins in diesel engine manufacturing into a broad industrial conglomerate serving multiple end markets, including agriculture, marine, construction industrial engines and energy systems. Today, Yanmar operates across the globe with the majority of its revenues generated outside Japan.

As a family-owned company, Yanmar has maintained a long-term strategic orientation that emphasizes innovation, technological excellence, product reliability, strong customer ties embedded in a reliable global aftermarket services platform and sustained value creation.

Yanmar has an impressive track record of acquiring and integrating businesses to accelerate growth and has in its dialogue with the Board expressed its conviction that completion of the Offer would establish a strong platform for long-term value creation by combining complementary technologies, expanding global market reach, and strengthening the combined groups’ position as a trusted partner to the global aquaculture industry. Yanmar has expressed that the Offer is intended to provide AKVA a platform to scale, by leveraging Yanmar’s capabilities, global resources and patient capital, as a long-term industrial owner.

“AKVA has built a unique position in the global aquaculture industry over more than five decades. Following a comprehensive strategic review and with strong support from our largest shareholders, we believe the Offer represents the best solution for both AKVA and our current shareholders. By combining AKVA’s industry-leading aquaculture expertise with Yanmar’s global industrial capabilities, technology base and long-term ownership perspective, we see substantial potential to create value for customers and further strengthen the Company’s growth and innovation agenda,” says Knut Nesse, CEO of AKVA Group.

“We are very pleased to have this opportunity to partner with AKVA, a company that has established a leading position in global aquaculture,” says Tetsuya Yamamoto, Executive Vice President and Representative Director of Yanmar Holdings Co., Ltd. “By combining complementary technologies and global resources, we believe there are exciting opportunities for AKVA and Yanmar to form a strong combination delivering next-generation integrated and technology-enabled solutions to sea-based and land-based aquaculture operators.”

Key terms of the Offer
AKVA’s shareholders will be offered NOK 161 per share in cash. The Offer values all issued and outstanding Shares at an aggregate of approximately NOK 5.9 billion.

No commission will be charged in connection with settlement of the Offer.

If the Company should resolve to distribute dividend or make any other distributions to the Company’s shareholders with a record date prior to completion of the Offer, the Offer Price shall be adjusted to compensate for the effects of such dividend or other distribution.

The formal and complete details of the Offer, including all terms and conditions thereof, will be included in an offer document for the Offer (the “Offer Document”) prepared by the Offeror and will be sent to AKVA’s shareholders with known addresses in jurisdictions who may lawfully accept the Offer following review and approval by the NFSA pursuant to Chapter 6 of the Norwegian Securities Trading Act. The Offer may only be accepted on the basis of the Offer Document.

The launch of the Offer is subject to customary conditions being satisfied, including that the Irrevocable Undertakings remain valid and in full force, that neither party has breached any of its obligations under the Transaction Agreement, and the approval of the Offer Document by the NFSA.

The Offer is not subject to any due diligence or financing condition. As will be further detailed and specified in the Offer Document, completion of the Offer will be subject to the following conditions (the “Closing Conditions”) being satisfied or waived by the Offeror, in whole or in part (acting in its sole discretion):

  1. Minimum Acceptance. The Offer shall on or prior to the expiration of the offer period have been validly accepted by shareholders of the Company representing, when taken together with any Shares acquired or agreed to be acquired by the Offeror other than through the Offer or which the Offeror is otherwise entitled to acquire, 90% or more of the issued and outstanding shares and voting rights of the Company on a fully diluted basis.
  2. Board Recommendation. The recommendation of the Offer issued by the Board, has not, without the Offeror’s written consent, been amended, qualified or withdrawn.
  3. Regulatory Approvals. Approvals or clearances (as applicable) of the completion of the Offer from (i) the Norwegian Competition Authority, and (ii) relevant authorities authorizing FDI clearance in Australia, Canada, Denmark, Lithuania, Greece and the United Kingdom on terms satisfactory to the Offeror (in its reasonable opinion) subject to the terms of the Transaction Agreement.
  4. Ordinary Conduct of Business. Except as explicitly provided for under the Transaction Agreement, that the business of the group, in the period until settlement of the Offer, has in all material respects been conducted in the ordinary course.
  5. No Legal Action. No court or governmental or regulatory authority of any competent jurisdiction, or other third party, shall have taken or threatened to take any form of legal action (whether temporary, preliminary or permanent) that will (A) restrain or prohibit the consummation of the Offer; or (B) in connection with the Offer impose conditions upon the Offeror, the Company or any of their subsidiaries or affiliates which would require the Offeror to incur any material expenditure, would prohibit or impair the Offeror or its affiliates or its ownership or operation of the group, or is reasonably likely to have a material adverse change.
  6. No Material Breach. There shall have been no material breach by the Company of the Transaction Agreement.
  7. No Material Adverse Change. No material adverse change shall have occurred between the date of the Transaction Agreement and until completion of the Offer.

The offer period under the Offer will commence following publication of the Offer Document and is expected to last for two weeks, subject to any extensions by the Offeror (up to a maximum offer period of 10 weeks in total) provided, however, that after the “Minimum Acceptance” condition has been satisfied, the Offeror may not extend the Offer Period by more than 10 business days.

Settlement of the Offer will be made within 10 business days after announcement that the Closing Conditions “Minimum Acceptance” and “Regulatory Approvals” have been met or waived, provided that the other Closing Conditions remain satisfied until such completion or are waived by the Offeror. If the Offeror has not publicly announced that the Closing Conditions “Minimum Acceptance” and “Regulatory Approvals” are satisfied or waived on or before 30 January 2027, the Offer will lapse, unless the deadline is extended by mutual agreement between the Offeror and the Company but under no circumstances beyond 30 May 2027.

Barring unforeseen circumstances, it is expected that the Offer will be completed in the fourth quarter of 2026.

If, as a result of the Offer, the Offeror acquires and holds 90% or more of all Shares (excluding treasury shares owned by the Company), the Offeror will have the right, and intends, to carry out a compulsory acquisition of the remaining Shares. Furthermore, if the Offeror acquires or holds a sufficient majority of the Shares, the Offeror intends to propose that the general meeting of the Company passes a resolution to apply for a de-listing of the Shares from Euronext Oslo Børs.

Transaction Agreement
Under the Transaction Agreement, the Board has agreed not to withdraw, modify, qualify or refrain from reaffirming its recommendation, except where the Board determines in good faith, after consultation with external legal counsel and, where relevant, its financial adviser, that maintaining the recommendation would be inconsistent with its fiduciary duties or applicable law. This may include circumstances where an unsolicited competing offer constitutes a superior proposal and is not matched by the Offeror within the agreed five-business-day matching period, the Offeror materially breaches the Transaction Agreement or fails to announce, launch or complete the Offer or maintain committed financing, or the Offer is amended in a manner adverse to AKVA or its shareholders. AKVA has also agreed to customary non-solicitation undertakings and to conduct its business in the ordinary course until completion, lapse or withdrawal of the Offer or termination of the Transaction Agreement.

Advisors
DNB Carnegie is acting as financial advisor and Wiersholm as legal advisor to the Company in connection with the Transaction.

Arctic Securities is acting as financial advisor and Arntzen Grette as legal advisor to Yanmar in connection with the Transaction.

Dated: 2 October 2026
AKVA group ASA

For further information, please contact:
Knut Nesse, Chief Executive Officer
Phone: +47 51 77 85 00
Mobile: +47 91 37 62 20
Email: knesse@akvagroup.com

Ronny Meinkøhn, Chief Financial Officer
Phone: +47 51 77 85 00
Mobile: +47 98 20 67 76
Email: rmeinkohn@akvagroup.com

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements according to section 5-12 of the Norwegian Securities Trading Act. The information was submitted for publication by Ronny Meinkøhn (CFO) on 2 October 2026 at 12:45 CET.

About AKVA group ASA
AKVA group ASA is a global technology and service partner that delivers technology and services that help solve biological challenges within the aquaculture industry. Good operational performance and fish welfare ensure sustainability and profitability for the customer. This is the premise for everything we deliver, from single components to services and complete installations. In-depth aquaculture knowledge, extensive experience and a high capacity for innovation characterize and enable us to deliver the best solutions for both land-based and sea-based fish farming.

About Yanmar
With beginnings in Osaka, Japan, in 1912, Yanmar was the first ever to succeed in making a compact diesel engine of a practical size in 1933. A pioneer in diesel engine technology, Yanmar is a global innovator in a wide range of industrial equipment, from small and large engines, agricultural machinery and facilities, construction equipment, energy systems, marine, to machine tools and components — Yanmar’s global business operations span seven domains. Guided by its Brand Statement, “A Sustainable Future – New Value Through Technology,” Yanmar provides advanced solutions to the challenges customers face on land, at sea, and in the city, working towards realizing a sustainable future.

IMPORTANT INFORMATION

The terms and conditions of the Offer will be governed by Norwegian law and carried out in conformity with the requirements of Norwegian law. The Offer and the distribution of this announcement and other information in connection with the Offer may be restricted by law in certain jurisdictions. When published, the Offer Document and related acceptance forms will not and may not be distributed, forwarded or transmitted into or within any jurisdiction where it is prohibited by applicable law, including, without limitation, Australia, Canada, Hong Kong, Japan, New Zealand, South Africa and South Korea, or any other jurisdiction in which it would be unlawful. The Offeror does not assume any responsibility in the event there is a violation by any person of such restrictions. Persons in the United States should review “Notice to U.S. Holders” below. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

This announcement is for information purposes only and is not an offer or a tender offer document and, as such, is not intended to constitute or form any part of an offer or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Offer or otherwise. Investors may accept the Offer only on the basis of the information to be provided in the Offer Document (if and when published). The Offer will not be made directly or indirectly in any jurisdiction where either an offer or participation therein is prohibited by applicable law or where any tender offer document or registration or other requirements would apply in addition to those undertaken in Norway.

Forward-looking statements

This announcement, oral statements made regarding the acquisition contemplated by the Transaction Agreement (the “Acquisition”) or the Offer, and other information published by AKVA, Yanmar or the Offeror, contain information and statements that may constitute “forward-looking information” or “forward-looking statements” under applicable securities legislation (“forward-looking statements”). Forward-looking statements are not historical facts and are generally, but not always, identified by words such as “will”, “plans”, “expects”, “is expected”, “estimates”, “forecasts”, “projects”, “intends”, “anticipates”, “aims”, “targets” or “believes”, or variations or negatives of such words, or by statements that actions, events or results “may”, “could”, “would”, “should”, “might” or “will” occur or be achieved. Forward-looking statements involve risks, uncertainties and other factors beyond the ability of AKVA, Yanmar and/or the Offeror to predict or control.

All statements other than statements of historical fact that address future events, developments or performance are forward-looking statements. These include statements regarding the expected timing and scope of the Acquisition; the launch and completion of the Offer; the satisfaction or waiver of conditions; and the expected effects of the Acquisition on AKVA, Yanmar or the Offeror. Such statements reflect current expectations and assumptions regarding future business strategies and operating environments.

Although AKVA, Yanmar and the Offeror believe that the expectations reflected in such forward-looking statements are based on reasonable assumptions, they involve known and unknown risks, uncertainties and other factors, most of which are beyond the control of such parties, that may cause actual results, performance or achievements to differ materially from those expressed or implied.

If one or more of these risks or uncertainties materialises, or if one or more assumptions prove incorrect, actual results may differ materially from those expected, estimated or projected. Neither AKVA, Yanmar, the Offeror, nor any member of their respective groups, nor any of their respective members, associates, directors, officers or advisers, gives any representation, assurance or guarantee that the events expressed or implied in any forward-looking statement will occur. Readers should therefore not place undue reliance on forward-looking statements.

All forward-looking statements in this announcement are made as of the date hereof and are based on opinions, estimates and information available as of that date. AKVA, Yanmar and the Offeror disclaim any intention or obligation to update or revise such statements, whether as a result of new information, future events or otherwise, except as required by law. The foregoing list of risks and uncertainties is not exhaustive.

No profit forecasts or estimates

No statement in this announcement is intended as a profit forecast or profit estimate and no statement in this announcement should be interpreted to mean that earnings or earnings per share for the current or future financial years would necessarily match or exceed the historical published earnings or earnings per share. Certain figures included in this announcement have been subjected to rounding adjustments. Accordingly, figures shown for the same category presented in different sections may vary slightly and figures shown as totals in certain sections may not be an arithmetic aggregation of the figures that precede them.

Notice to U.S. Holders

Holders of Shares in the United States (“U.S. Holders”) are advised that the Shares are not listed on a U.S. securities exchange and that AKVA is not subject to the periodic reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act”), and is not required to file reports with the U.S. Securities and Exchange Commission thereunder.

The Offer will be made for the issued and outstanding Shares of AKVA, other than Shares held by AKVA, and will be subject to Norwegian disclosure and procedural requirements, which differ from those of the United States. If made to U.S. Holders, the Offer is expected to be made as a “Tier I” tender offer under Rule 14d-1(c) of Regulation 14D under the U.S. Exchange Act, to the extent applicable and subject to available exemptions, and otherwise in compliance with Norwegian disclosure and procedural requirements, including with respect to the timetable, settlement procedures and timing of payments.

The Offer will be made to U.S. Holders on the same terms and conditions as those made to all other holders of Shares to whom the Offer is made. Any information document, including the Offer Document, will be disseminated to U.S. Holders in English on a basis comparable to the method that such documents are provided to AKVA’s other shareholders to whom the Offer is made. The Offer will be made by the Offeror and no one else. U.S. Holders are encouraged to consult with their own advisors regarding the Offer.

To the extent permissible under applicable law or regulations, the Offeror and its affiliates or brokers (acting as agents for the Offeror or its affiliates, as applicable) may from time to time and during the pendency of the Offer, and other than pursuant to the Offer, directly or indirectly, purchase or arrange to purchase, Shares or any securities that are convertible into, exchangeable for or exercisable for such Shares outside the United States, so long as those acquisitions or arrangements comply with applicable Norwegian law and practice and the provisions of such exemption. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices.

To the extent information about such purchases or arrangements to purchase is made public in Norway, such information will be disclosed by means of an English language press release via an electronically operated information distribution system in the United States or other means reasonably calculated to inform U.S. Holders of such information. In addition, the financial advisor to the Offeror may also engage in ordinary course trading activities in securities of the Company, which may include purchases or arrangements to purchase such securities as long as such purchases or arrangements are in compliance with applicable law. To the extent required in Norway, any information about such purchases will be made public in Norway in the manner required by Norwegian law.

Neither the U.S. Securities and Exchange Commission nor any U.S. state securities commission has approved or disapproved the Offer, passed upon the merits or fairness of the Offer, or passed any comment upon the adequacy, accuracy or completeness of the disclosure in this announcement. Any representation to the contrary is a criminal offense in the United States.

It may be difficult for the Company’s shareholders to enforce their rights and any claims they may have arising under the U.S. federal securities laws in connection with the Offer, since the Offeror and the Company are located in non-U.S. jurisdictions, and some or all of their respective officers and directors may be residents of non-U.S. jurisdictions. The shareholders of the Company may not be able to sue the Offeror or the Company or their respective officers or directors in a non-U.S. court for violations of the U.S. federal securities laws. It may be difficult to compel the Offeror and the Company and their respective affiliates to subject themselves to a U.S. court’s judgment.

Attachment

Anchorage, Alaska, Oct. 02, 2026 (GLOBE NEWSWIRE) — Nova Minerals Corp (“Nova Minerals” or the “Company”) (NYSE American: NVA | ASX: NVA) is pleased to invite shareholders, investors, and the broader market to attend an Investor Webinar for an update on the Company’s recent efforts at its Estelle Gold and Critical Minerals Project in Alaska, and antimony supply chain capabilities.

Nova Chief Executive Officer Christopher Gerteisen will present on the Company’s recent progress towards developing antimony processing and refining capabilities at Port MacKenzie, and ultimately establishing a secure, integrated antimony domestic supply chain funded by a US$43.4 million award from the U.S. Department of War.

Mr. Gerteisen will also cover highlights from the recent field season at Estelle, which is one of North America’s largest undeveloped gold assets, with a multi-million-ounce resource and significant growth potential.

RedChip will be hosting the Investor Webinar. If attendees are unable to join the event on the day of the conference, an archived webcast will also be made available on the Company’s website www.novamineralscorp.com and YouTube channel.

RedChip Companies Webinar
Time: 4.15 pm US EDT Wednesday October 7, 2026
        7.15 am Australian AEDT Thursday October 8, 2026

Registration: To register for the free webinar, please visit:
https://www.redchip.com/webinar/NVA/83073728095

Questions: Questions may be submitted in advance to NVA@redchip.com

Further discussion and analysis of the Estelle Project is available through the interactive Vrify 3D animations, presentations, and videos, all available on the Company’s website www.novamineralscorp.com

About Nova Minerals Corp

Nova Minerals Corp is advancing one of the world’s largest undeveloped gold deposits into production and securing a U.S. domestic supply of the critical mineral antimony. The Company is focused on the exploration and development of the Estelle Gold and Critical Minerals Project, located in Alaska, a tier-one mining jurisdiction.

Estelle hosts two defined multi-million-ounce gold resources, and more than 20 prospects distributed along a 35-kilometre mineralized trend, in the prolific Tintina Gold Belt, a province which hosts a >220 million ounce (Moz) documented gold endowment and some of the world’s largest gold mines and discoveries, including Kinross Gold Corporation’s Fort Knox Gold Mine. In parallel, Nova is advancing its critical minerals strategy, fully funded by a US$43.4 million U.S. Department of War award to develop a domestic antimony supply chain, targeted for production in 2027.

Further discussion and analysis of the Estelle Project is available through the interactive Vrify 3D animations, presentations, and videos, all available on the Company’s website www.novamineralscorp.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical fact, contained in this press release are forward-looking statements and are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nova Minerals Corp’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and Nova Minerals Corp undertakes no duty to update such information except as required under applicable law.

For further information:

Nova Minerals: Media: Investor Relations:
Craig Bentley Jenna Shinderman Dave Gentry, CEO
Executive Director Sodali & Co RedChip Companies, Inc.
Ph: 1-720-550-4223 Ph: 1-631-918-4047 Ph: 1-407-644-4256
E: craig@novamineralscorp.com E: jenna.shinderman@sodali.com E: NVA@redchip.com

STOCKHOLM, SWEDEN – BTS Group AB (publ), a leading global consultancy specializing in strategy execution, change, and people development, has signed a USD 12.8M deal to provide AI enablement and implementation services on behalf of a leading, global company. The contract covers Q3 and Q4 2026, as well as Q1 2027, with the majority occurring in Q4 2026.

This deal is a result of BTS evolution to become the preferred partner for companies to develop a self-reliant, continually renewing AI culture and skillset.

“This win is a testament to our successful move into the large and growing market for supporting large companies in launching AI into their businesses. Our approach provides the alternative to outsourcing AI innovation, and instead, upskills the experts who know their business best – their own people” Jessica Skon, BTS CEO, states.

For more information, please contact:
Rodney Alfvén
Head of investor relations
BTS Group AB
Rodney.Alfven@bts.com  
+46 72 235 05 15

About BTS Group AB
BTS is a global professional services firm headquartered in Stockholm, Sweden. BTS has about 1,100 professionals in 35 offices located on six continents. BTS competes in both talent and HR consulting as well as the traditional consulting markets. BTS’s services support a broad range of client challenges including top-to-bottom and on-demand leadership development, talent selection and readiness, strategy creation and strategy implementation, as well as culture and broad-scale change. For 40 years, BTS has been focused on the people-side of change and on powering better performance using proprietary simulation, learning, coaching, and assessment methodologies. We partner with nearly 1,200 organizations, including over 40 of the world’s 100 largest global corporations.

BTS is a public company listed on the Nasdaq Stockholm exchange and trades under the symbol BTS B.

For more information, please visit www.bts.com.

Attachment

Transaction in Own Shares

October 01, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 01 October 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency
01/10/2026 875,000 £ 35.9650 £ 35.0450 £ 35.5937 LSE GBP
01/10/2026 – – – – Chi-X (CXE) GBP
01/10/2026 – – – – BATS (BXE) GBP
01/10/2026 425,000 € 42.3450 € 41.1700 € 41.7419 XAMS EUR
01/10/2026 – – – – CBOE DXE EUR
01/10/2026 – – – – TQEX EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026. 

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of the following facilities:

  • Delta Post Acute and Rehabilitation, an 80-bed skilled nursing facility located in Delta, CO;
  • La Villa Grande Care Center, a 96-bed skilled nursing facility located in Grand Junction, CO;
  • Milestone Health and Rehabilitation, a 190-bed skilled nursing facility located in Littleton, CO;
  • Monument Ridge Health and Rehabilitation, an 88-bed skilled nursing facility located in Grand Junction, CO;
  • Pendant Health and Rehabilitation, a 130-bed skilled nursing facility located in Lakewood, CO;
  • Skyline Ridge Health and Rehabilitation, a healthcare campus with 85 skilled nursing beds and 47 independent living units located in Canon City, CO; and
  • Springs Village Care Center, a 91-bed skilled nursing facility located in Colorado Springs, CO.

Each facility is operated by an Ensign affiliated operator and subject to a long-term triple net lease. This acquisition was effective as of October 1, 2026.

“We are delighted to expand our longstanding presence in Colorado with the addition of these facilities,” said Barry Port, Ensign’s Chief Executive Officer. “Ensign has served communities across Colorado for many years, and these operations fit well within the existing footprint while expanding our presence on the Western Slopes.”

David Jorgensen, President of Endura Healthcare LLC, Ensign’s Colorado-based subsidiary, added “Each of these communities has a dedicated group of caregivers committed to serving residents at a high level. Our focus will be on supporting local leadership, strengthening clinical programs and creating an environment where caregivers can thrive while delivering exceptional outcomes for those entrusted to our care.”

In an additional transaction on the same day, Ensign announced that it acquired the operations of eight facilities in Florida comprised of 713 additional skilled nursing beds and 66 independent living units. Every facility is operated by an Ensign affiliated operator and is subject to a long-term triple net lease. In another transaction on the same day, Ensign announced that it acquired the real estate and operations of “Englewood Heights Nursing and Rehabilitation”, a 118-bed skilled nursing facility located in Pensacola, Florida. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign’s captive real estate company, and the facility is operated by an Ensign-affiliated tenant.

In a separate transaction on the same day, Ensign announced that it acquired the operations of four facilities in Washington comprised of 532 additional skilled nursing beds. Each of these facilities is operated by an Ensign affiliated operator and is subject to a long-term triple net lease.

Additionally, Ensign announced that through subsidiaries of Standard Bearer Healthcare REIT, Inc. it acquired the real estate assets of five facilities that had previously been operating under third-party triple net leases. These facilities total 755 skilled nursing beds and are now subject to long-term leases with subsidiaries of Standard Bearer.

As of today, Ensign’s growing portfolio consists of 418 healthcare operations, which includes 50 senior living operations, across 18 states. Ensign subsidiaries, including Standard Bearer, own 189 real estate assets. Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living and other healthcare related businesses throughout the United States.

About Ensign™

The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 418 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, ir@ensignservices.net

SOURCE: The Ensign Group, Inc.

SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the EnsignTM group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of four facilities in Washington (i) “Burien Nursing and Rehabilitation”, a 140-bed skilled nursing facility located in Burien, WA; (ii) “Issaquah Nursing and Rehabilitation”, a 140-bed skilled nursing facility located in Issaquah, WA; (iii) “Park Ridge Nursing and Rehabilitation”, a 115-bed skilled nursing located in Shoreline, WA; and (iv) “Park West Nursing and Rehabilitation”, a 137-bed skilled nursing facility located in Seattle, WA. Each of these facilities is operated by an Ensign affiliated operator and is subject to a long-term triple net lease.

“The addition of these facilities represents an exciting opportunity to strengthen our presence in the Pacific Northwest and further expand our operations in Washington,” said Barry Port, Ensign’s Chief Executive Officer. “These facilities serve vibrant communities throughout the Seattle area, and we have tremendous confidence in our local leadership teams and their ability to support strong clinical programs while maintaining a resident-centered approach to care.”

Steve Farnsworth, President of Pennant Healthcare LLC, Ensign’s Washington-based subsidiary, added “These facilities have long served as important healthcare resources in their communities, and we are excited to build upon that legacy. Our local teams look forward to working closely with these amazing caregivers as we continue enhancing care for the residents and families in these communities.”

In an additional transaction on the same day, Ensign announced that it acquired the operations of eight facilities in Florida comprised of 713 additional skilled nursing beds and 66 independent living units. Every facility is operated by an Ensign affiliated operator and is subject to a long-term triple net lease.

In a separate transaction on the same day, Ensign announced that it acquired the real estate and operations of “Englewood Heights Nursing and Rehabilitation”, a 118-bed skilled nursing facility located in Pensacola, Florida. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign’s captive real estate company, and the facility is operated by an Ensign-affiliated tenant.

In another transaction on the same day, Ensign announced that it acquired the operations of seven facilities in Colorado comprised of 760 additional skilled nursing beds and 47 independent living units. All seven facilities are operated by an Ensign affiliated operator and are subject to a long-term triple net lease.

Additionally, Ensign announced that through subsidiaries of Standard Bearer Healthcare REIT, Inc. it acquired the real estate assets to five facilities that it had previously been operating under third-party triple net leases. These facilities total 755 skilled nursing beds and are now subject to long-term leases with subsidiaries of Standard Bearer.

As of today, Ensign’s growing portfolio consists of 418 healthcare operations, which includes 50 senior living operations, across 18 states. Ensign subsidiaries, including Standard Bearer, own 189 real estate assets. Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living and other healthcare related businesses throughout the United States.

About EnsignTM

The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 418 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, ir@ensignservices.net

SOURCE: The Ensign Group, Inc.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.